# A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

> **NCT00398710** · PHASE2 · COMPLETED · sponsor: **AEterna Zentaris** · enrollment: 37 (actual)

## Conditions studied

- Waldenström's Macroglobulinemia

## Interventions

- **DRUG:** Perifosine

## Key facts

- **NCT ID:** NCT00398710
- **Lead sponsor:** AEterna Zentaris
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2011-08
- **Final completion:** 2011-10
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398710, "A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00398710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*